• HealthLynked achieved significant optimization in operational expenses, resulting in a 70% reduction in net loss for the fourth quarter and highlighting a period of strategic positioning for future growth
• HealthLynked’s full-year 2023 financial results mark technological advancements, with a focus on core technologies and profitability
• The company anticipates further performance improvements in the second half of 2024, positioning itself as a leader in healthcare technology

HealthLynked (OTCQB: HLYK), a leader in healthcare networking and technological innovation, recently announced its financial results for the fourth quarter and full year ending December 31, 2023. HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of strategic advancements and focus on healthcare technologies plus networking capabilities (https://ibn.fm/ycgvs).

Dr. Michael Dent, CEO of HealthLynked said the recent launch of the pay app version 3.2.1 and the forthcoming integration of ARI mark significant milestones in the company’s mission to transform healthcare delivery and drive additional revenues. “Despite temporary staffing transitions, our focus on our core healthcare network and technological innovations position us for substantial growth and profitability,” Dr. Dent said. “We continue to grow our user base while integrating technology that improves patient care and the efficient exchange of medical information between doctors and patients.”

HealthLynked’s full-year 2023 financial results reflect investments in technological advancements that will accelerate revenue growth in our core technology application. Despite a modest 2% revenue decrease attributed to temporary staffing adjustments and the onboarding of new physicians, the release of the new pay app version 3.2.0, together with the integration of our Artificial Intelligence – ARI – into the HealthLynked app, present promising opportunities for core revenue growth.

Operational efficiency was notably improved with a 52% cut in operational losses and a 19% reduction in operating expenses, signaling HealthLynked’s commitment to financial stewardship. The strategic divestiture of ACO Health Partners bolstered financial restructuring, contributing $3.76 million and enhancing liquidity. A dramatic reduction in net loss to $1.01 million from $8.82 million in 2022 showcases the positive impact of strategic divestitures and operational efficiencies.

In the fourth quarter of 2023, revenue declined to $0.93 million due to temporary physician staffing adjustments, yet strategic initiatives led to a 73% reduction in operating loss and a 70% reduction in net loss, demonstrating resilience and adaptability amidst staffing transitions and emphasizing a commitment to long-term financial sustainability and growth. With a focus on core technologies and profitability, HealthLynked anticipates improved performance in the second half of 2024, positioning itself as a leader in healthcare technology.

The global patient-centric healthcare app market was valued at $18.65 billion in 2024. It is expected to reach 100.66 billion by 2029, growing at a CAGR of 40.11% during the forecast period (https://ibn.fm/FXFJn). The market is expected to grow because patients are more inclined to use apps to manage their chronic conditions, such as diabetes, hypertension, and more. The COVID-19 pandemic showed a positive impact on the market, and more apps have been launched in response to providing medical care to patients in more convenient methods.

The HealthLynked App is uniquely situated to take advantage of the explosive growth in that market as it is the only comprehensive network that addresses most of the problems in the healthcare industry.  As a result, demand for the app should be high as more features and services are added over time.

By concentrating on our core technologies and healthcare network, HealthLynked is poised to advance more profitably, continuing to innovate and lead in the healthcare sector.

HealthLynked maintains a steadfast commitment to advancing healthcare innovation through strategic focus and technological progress. The company deeply appreciates the ongoing support of its investors and stakeholders as it navigates these transitions and moves forward toward a future characterized by expansion, innovation, and improved healthcare results.

For more information, visit the company’s website at www.HealthLynked.com.

NOTE TO INVESTORS: The latest news and updates relating to HLYK are available in the company’s newsroom at https://ibn.fm/HLYK

Zevra Therapeutics (NASDAQ: ZVRA), a rare disease therapeutics company, uniquely combines data-driven techniques, patient needs and outside the box strategies while challenging moribund drug development protocols to bring new therapeutic relief to millions of people suffering with rare diseases. With a team of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus – Zevra intends to become a global leader in developing and commercializing treatments for rare diseases that have limited or no therapeutic options. The company’s recent Letter to Stockholders reveals what looks like a launch code for success and suggests the company is on a fast track to drive value for all its stakeholders – patients and caregivers, stockholders, investors, and employees.

In the letter, Neil F. McFarlane, President and CEO, highlighted recent achievements and, importantly, outlined the vision for the company’s future. McFarlane began his tenure by instilling a couple of prime directives that have become guiding principles for the Zevra team. The first directive has become the company mantra, “What’s best for the patient?”, and patient outcomes now guide daily decisions. The second directive McFarlane instilled, “We must execute.”, drives value not just for patients but for all stakeholders – he believes that by defining a clear strategy, creating effective tactics to reach strategic objectives, then executing at the highest level will create and drive value, and help propel Zevra into global leadership in developing and commercializing rare disease therapeutics. Hard to argue with his directives, Zevra is fast making huge strides in reaching objectives.

Zevra has already made significant progress advancing its rare disease portfolio and made demonstrable progress in adroitly executing key strategic priorities. In November 2023, the company completed a shrewd, capital-efficient acquisition of Acer Therapeutics. That acquisition allowed Zerva to immediately start delivering value to patients by commercializing OLPRUVA(R) for treatment of urea cycle disorders (“UCDs”). UCDs are related to defects of enzymes involved in the urea cycle which can lead to high toxic features of ammonia-like irreversible brain damage, coma, and death.

Immediately after the acquisition, Zerva deployed a systematic strategy to build awareness with physicians across the country about OLPRUVA for people living with UCDs. In the three months since launch, Zerva’s team also engaged with over 90% of its customers. The company concurrently achieved meaningful growth in reimbursement coverage, from ~55% of U.S. covered lives at the time of acquisition, to now more than 70%.

The full commercial launch of OLPRUVA at the end of January 2024 was designed to provide scale and cost synergies to support and accelerate the launch and commercialization of arimoclomol to treat Niemann-Pick Disease. Affecting mostly children, Niemann-Pick is a group of rare genetic conditions that affect the body’s ability to break down and use fats, such as cholesterol and lipids, inside cells, and over time, the cells die worsening the function of the nerves, brain, and other organs. With no known cure and sometimes fatal, Zerva’s arimoclomol could be the lifeline so many children need.

Exemplifying the prime directives, the entire Zerva team put forth enormous effort to submit a comprehensive data set to the U.S. Food and Drug Administration (“FDA”) supporting the resubmission of the New Drug Application (“NDA”) for arimoclomol. In March, Zerva announced that the FDA had extended the review period for the NDA, resulting in a revised Prescription Drug User Fee Act (“PDUFA”) date of September 21, 2024.

Also in March, Zerva reported positive top-line data from its Phase 2 study of KP1077 in patients with idiopathic hypersomnia (“IH”). Initial results show that KP1077 is well tolerated and demonstrates early signs of differentiated and meaningful clinical benefits. Topline data from the completed trial are expected in the first half of 2024 and represent another potential Zevra commercial candidate.

Zerva fully intends to bring life-changing therapeutics to people living with rare diseases through expertise, elegant solutions, and transparent data narratives which have already produced a late-stage rare disease clinical pipeline and two partnered commercial products.

But blockbusters and breakthroughs don’t happen in a vacuum. It takes a dedicated and committed team of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus with a proven record of bringing new therapies to patients…. and Zerva is loaded with talent.

Zerva is building a team of talented professionals committed to using science and data-driven development approaches to create and deliver new therapies to address critical and often overlooked unmet needs. Since announcing the strategic objective of becoming a leading rare disease company in the first half of 2022, Zerva has grown its team of skilled professionals through both recruiting and acquisitions, from a team of 24 to 81. It’s important to note that this personnel ramp-up includes the buildout of targeted customer-facing commercial and medical affairs teams with decades of experience in rare diseases. The company also added Adrian Quartel, M.D. as Zevra’s Chief Medical Officer, who brings more than 20 years of experience with a track record of success in clinical development, pharmacovigilance and medical affairs addressing the needs of the rare disease community. Such powerful commercial and clinical muscle are likely to really drive value and bode well for the future of the company.

Zevra Therapeutics leverages decades upon decades of collective experience in drug development and regulatory machinations to develop therapies faster and overcome challenging regulatory situations. Rare diseases may finally be reigned-in and held at bay by combining science, data, and patient needs with a team of dedicated professionals to create transformational therapies and bring life-changing therapeutics to millions of people living with rare diseases. Look for more exciting news from Zerva in the months to come.

For more information, please visit www.Zevra.com.

• 150+ Americans die every day from synthetic opioid (e.g. fentanyl) overdose
• Nutriband’s AVERSA(TM) Fentanyl technology is being developed as an innovative solution to abuse and misuse rates in prescription opioid patch medications
• Nutriband raised $8.4 million in a private placement to fund AVERSA Fentanyl through FDA Approval Process

Fentanyl addiction continues to devastate communities, with current treatment options facing limitations. However, as often happens in healthcare, innovation breeds hope with a new option on the horizon planning to seek FDA marketing approval.

The challenges related to the powerful painkiller (up to 50x stronger than heroin and 100x stronger than morphine) are well documented. According to the Centers for Disease Control and Prevention, more than 150 Americans die every day from overdoses related to synthetic opioids like fentanyl.

Nutriband (NASDAQ: NTRB) is looking to provide a much-needed new option for managing severe and chronic pain that requires the use of an opioid (https://ibn.fm/7AYt6). The Orlando-based company stated last month that it raised gross proceeds of $8.4 million towards the remaining clinical development of AVERSA(TM) Fentanyl and submission of its New Drug Application (“NDA”) with the U.S. Food and Drug Administration.

If approved, transdermal delivered AVERSA(TM) Fentanyl would become the world’s first opioid patch with abuse deterrent properties.

In its 2022 market analysis report of AVERSA(TM) Fentanyl, Health Advances, a leading healthcare consulting company, estimated peak U.S. sales of the new product between $80 million to $200 million.

The private placement was completed through the sale of 2.1 million shares of NTRB common stock at $4.00 per share, with each share purchased also entitling the purchaser to a warrant to purchase two more shares at a price of $6.43 per share, a sharp premium from the current price.

Products addressing chronic pain are the most advanced in Nutriband’s pipeline where its AVERSA(TM) platform technology is applicable. The company has added buprenorphine and methylphenidate to its development pipeline. Buprenorphine is also a medication used to treat opioid addiction, including addiction to heroin and other prescription painkillers. While very helpful because of its “ceiling effect,” meaning analgesia, euphoria, and respiratory depression plateau at high doses, buprenorphine still has the potential for abuse.

As it happens, the AVERSA(TM) abuse deterrent technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Other areas of focus for Nutriband’s transdermal expertise include attention deficit hyperactivity disorder (“ADHD”), Type 2 diabetes, and infertility. While those developments take shape, all eyes will be on the NDA filing with the FDA and what that can mean for new therapeutics to help combat the opioid dilemma.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

ZJ Events invites entrepreneurs, traders, and regulatory authorities from the alternative products spectrum, and all enthusiasts of the counterculture industry, to attend the Vape South America 2024 Medellin event. The tradeshow will be held at the Plaza Mayor Convention Center, Medellin, Colombia, May 18-19, 2024.

Veteran leaders, top manufacturers and traders, as well as major investors looking for novel avenues of business, will be there. ZJ Events is committed to offering the alternative products community an expansive learning, networking, and business forum, presented in an inviting and safe environment.

Buyers, head shop owners, and dealers of alternative products, will exhibit their unique and trending products and services. Attendees can also avail huge discounts and show-exclusive deals on a vast array of alternative products, including herbal products, vape products, functional beverages, dietary supplements, mood enhancers, nootropics, and more.

Hundreds of leading brands will be shown at the exhibitor booths. Thousands of registered buyers visit the expo to get latest updates, understand the trends, and bag the best deals in the market. The advertising done by the ZJ Events team attracts high-level buyers and top investors looking for the latest and most unique ideas and products. Associated media attention and outreach encourage many upcoming and talented brands to be introduced.

Marketing and trading of alternative products has always been a challenging task as these products often do not find a major place in conventional distribution and marketing. Hence, this expo, organized by ZJ Events, offers alternative products a robust platform where buyers, sellers, creative minds, and investors, can showcase their products, while connecting and collaborating on a long-term basis.

To learn more, please visit https://ibn.fm/uuJnZ.

Industry experts, senior bankers, fintech leaders, entrepreneurs, innovators, investors, and financial institutions from around the globe, are invited to attend the FinovateSpring conference being held on May 21-22, 2024, in Marriott Marquis San Francisco, San Francisco, CA. The important event is gearing up for its 2024 edition and promises an unmatched showcase of advanced fintech technology and networking opportunities. The two-day event will serve as a catalyst for collaboration, key contacts, and advanced fintech solutions.

Businesses today need to embrace the latest technologies and stay ahead of competitors for improved growth and customer experience. FinovateSpring is the West Coast’s leading fintech event that provides an exclusive platform for established businesses and startups to showcase their innovative products, services, and solutions. Featuring live demos and presentations, the event offers attendees a firsthand look at state-of-the-art fintech solutions.

Bigger and Better Fintech Evolution

The 2024 edition of FinovateSpring will feature a prominent lineup of visionaries set to take the stage and share important insights into the latest trends and challenges facing the fintech industry. The event provides attendees with a great opportunity to connect with potential partners, investors, and customers. Attendees can get expert advice across a wide range of categories, including digital banking, lending, wealth management, payments, insurtech, regtech, and more.

FinovateSpring is a community of like-minded professionals who are committed to driving innovation and collaborating on fintech solutions. Attendees can leverage specialized workshops focused on practical strategies for navigating the fintech landscape. Representative speakers for the event include J.P. Morgan, Cornerstone Advisers, Charles Schwab, U.S. Bank, BNY Mellon, HSBC, University of California, Women in Payments, Wells Fargo, Cota Capital & more.

To learn more, please visit https://ibn.fm/cMczz

• TMET.V has 100% ownership in three highway-accessible gold and copper projects that remain largely untested by drilling, covering 1,000 square kilometers within prolific mining districts of Ontario and British Columbia
• Exploration projects include the Filion Gold Project with significant gold potential evidenced by historical sampling, the Kolos Copper-Gold Project showing high-grade values in surface sampling coincident with anomalous geophysics extending 1.5 kilometers into the sub-surface, and the Latham Copper-Gold Project featuring multiple promising anomalies and high-grade rock grab samples in addition to a historical copper-gold porphyry deposit
• Favorable market conditions driven by renewable energy and electric vehicle industries have led to increased copper demand, prices recently reached $10,000/ton

Torr Metals (TSX.V: TMET), a Canada-based mineral exploration company advancing mineral properties in Ontario and British Columbia, Canada. With 100% owned gold and copper projects spanning 1,000 square kilometers, the company aims to unlock the potential of its properties with a focus on cost-effective exploration and development aided by proximity to existing major infrastructure.

TMET’s exploratory activities sync with favorable market conditions driven by the burgeoning renewable energy and electric vehicle industries. Limited copper supply is leading to increased demand by these sectors with a corresponding price increase to nearly $10,000 per ton (https://ibn.fm/hDubI). As a result, investors anticipate a bullish outlook for copper over the next few months driven by rising demand and tightening market conditions.

TMET aims to capitalize on the rising demand for these precious metals by advancing three key exploration projects in its portfolio. The Filion Gold Project, located in Ontario, spans 261 square kilometers, holding significant exploration potential with six unexplored gold targets along the Filion Fault – a known gold host. Historical sampling has confirmed the project’s high-grade gold potential, with rock grab samples reaching up to 9.1 g/t Au and channel sampling hitting 91.4 g/t Au over 0.3m. Recent soil sampling further highlights the company’s positive outlook, with assays hitting up to 1.32 g/t Au within a significant untested soil anomaly measuring 1200 meters in strike-length.

TMET’s Kolos Copper-Gold Project covers 140 square kilometers in British Columbia. The company aims to explore the area’s untapped copper porphyry potential, with recent surface geochemical and sub-surface geophysical results drawing comparisons to regional deposits including the Highland Valley and Copper Mountain Mines(*). Historical rock grab samples have shown high-grade values, with assays up to 4.24 g/t Au, 0.52% Cu, and 11.3 g/t Ag. Recent results published in March and April 2024 indicate 5 significant kilometer-scale copper soil anomalies with coincident geophysics suggesting mineralization could extend up to 1.5 kilometers depth. None of these exploration targets have ever been drilled, providing multiple potentials for a major new copper discovery.

Rounding out the company’s portfolio is the Latham Copper-Gold Project spanning 689 square kilometers in renowned Golden Triangle of British Columbia. Exploration targets include five never-drilled copper-gold soil anomalies defined in 2022 and 2023, as well as the Gnat Pass copper-gold porphyry deposit where historical drilling yielded significant intercepts including 0.64% Cu over 73 meters within broader mineralization extending from surface to over 200 meters vertical depth where it remains open. High-grade rock grab samples from outcrop have also shown recent promising results at-surface on the Dalvenie target, with values reaching up to 14.15 g/t Au, 4.31% Cu, and 63.1 g/t Ag.

TMET’s executive team brings decades of experience in exploration and project development across the Americas. With a portfolio of promising projects in strategic locations, the company is strongly positioned to leverage the surging demand for strategic minerals required by the growing electric vehicle and renewable energy industries.

(*)Comparisons are not necessarily indicative of mineralization on the Kolos Project.

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

• SenesTech, a rodent fertility control company, through its ContraPest(R) and patent-pending Evolve(TM) soft bait lines, is offering an effective, humane, and safe approach to controlling rat populations, and the diseases rodents can bring with them
• The company’s growing success speaks to the superiority of the company’s offerings, along with the overall effectiveness of its products

SenesTech (NASDAQ: SNES), the inventor of the only EPA-registered contraceptive for male and female rats, recognizes the risks associated with growing rodent populations, especially in cities and areas with a substantial human population. Following its years of experience in the field, the company understands the value of a humane and hygienic approach to controlling rat populations, with non-poison approaches that don’t threaten other animals. This has driven the development of its unique and effective products, and has given it a major competitive edge over its peers in the sector, promoting the company’s rapid and continuing sales increase.

With its fertility control products, SenesTech offers a proven way for entire cities and urban areas to reduce rat populations by over 90%. Available in a variety of delivery systems, SenesTech’s products allow for easy and efficient product deployment, an approach that is achieving significant acceptance in the market (https://ibn.fm/W25DI).

SenesTech’s approach is much needed throughout the industrialized and agricultural world, particularly factoring in how rodents can directly transmit a range of pathogens and disease. They have been known to cause human diseases such as hantavirus, rat bite fever, salmonellosis, and leptospirosis. In addition, these rodents have been known to host pests such as fleas and ticks, which transmit other diseases including, but not limited to, plague, tularemia, Lyme disease, and tickborne relapsing fever (https://ibn.fm/9wDor).

The situation is made worse, given how fast rodents can reproduce. Despite having an average lifespan of 9-12 months, many mice and rat species sexually mature as early as 4-5 weeks of age and have a gestation period of only 21 days. With the right environment, which entails adequate food and warm habitat, rats can have six litters a year, consisting of up to 18 pups each (https://ibn.fm/bw4sV). As such, unless addressed as early as possible, these populations can get out of hand quickly and wreak havoc, both from an environmental and a health perspective.

To address this, SenesTech has been advocating non-lethal rodent birth control products added to or separate from existing integrated pest management plans. Their products can be used separately, or in conjunction with additional rodent control methods.

“The most [effective approach] is combining the elements of integrated pest management and having them work together and support each other,” noted Joel Fruendt, SenesTech’s CEO. (https://ibn.fm/UDul0).

SenesTech’s management is optimistic that as time progresses, more people will learn of the value of its offerings and adopt its solutions. According to them, it speaks of the superiority of its solutions, the company’s market positioning, and the overall value it delivers to its customers.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Tartisan originally released a Preliminary Economic Assessment (“PEA”) report in 2022, which confirmed the significant nickel-copper-cobalt mineral resource at its 100%-owned Kenbridge Nickel Project
• The PEA noted that the measured and indicated mineral resources represent 3,508,000 tons at 0.70% Ni, 0.35% Cu, and 0.01% Co (54 Mlb Ni, 27 Mlb Cu), while inferred mineral resources represent 1,013,000 tones at 1.21% Ni, 0.56% Cu, and 0.01% Co (27 Mlb Ni, 13 Mlb Cu)
• The PEA also indicated a 9-year mine plan based on a 1,500-ton-per-day underground mining and processing operation
• The company transitioned to the Advanced Exploration (“AEX”) and Project Development Phase following the release of the PEA
• The Advanced Exploration and Project Development Phase is designed to expand the company’s understanding of the Kenbridge Deposit and enhance the current resource

Located in the Kenora Mining Division in northwestern Ontario, the Kenbridge Nickel Project is the flagship project of Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA), a Canadian mineral exploration and mining development company. The project has an existing shaft to a depth of 622 m (2,042 ft), with level stations at 45 m (150 ft.) intervals below the shaft collar and two levels developed at 107 m (350 ft) and 152 m (500 ft) below the shaft collar. Accessible by gravel roads from paved Highway 71, it is covered by patented and unpatented mining claims totaling 4,108.42 ha and registered to wholly owned subsidiaries of Tartisan Nickel.

Historical exploration and project development of the Kenbridge Nickel Project took place between 1936 and 2008. And during this period, five main companies completed mineral prospecting, geological mapping, geophysical surveys, trenching, and drilling programs.

Tartisan nonetheless acquired 100% of the Kenbridge Property from Canadian Arrow in 2018 and embarked on refurbishing the access road into the site and reestablishing the cut-line grid. The company then completed an ASTER LWIR imagery study in 2020, followed by a surface time domain electromagnetics survey and a borehole electromagnetic survey in the spring of 2021. Later in 2021, the company commenced drilling, the first drilling program since 2008.

The company completed ten drill holes totaling 8,988 m on the Kenbridge Nickel Project and four additional drill holes totaling 2,419 m on the Kenbridge North target as part of the 2021 drilling program. These drill holes brought the total number of drill holes completed on the property to 665, all totaling a drilling length of 99,741 m, according to the Preliminary Economic Assessment (“PEA”) report independently prepared by P&E Mining Consultants Inc. (https://ibn.fm/549xs).

Drilling and assay data provided by Tartisan and compiled, verified, and validated by P&E were used to create an updated MRE, which confirmed that the Kenbridge Project “contains a significant nickel-copper-cobalt mineral resource that is potentially amenable to underground mining.” The PEA noted that the measured and indicated mineral resources represent 3,508,000 tons at 0.70% Ni, 0.35% Cu, and 0.01% Co (54 Mlb Ni, 27 Mlb Cu), while inferred mineral resources represent 1,013,000 tones at 1.21% Ni, 0.56% Cu, and 0.01% Co (27 Mlb Ni, 13 Mlb Cu) (https://ibn.fm/szYAB).

Additionally, the PEA indicated a 9-year mine plan based on a 1,500-ton-per-day underground mining and processing operation. This mine plan assumes the potentially extractable tonnage of measured, indicated, and inferred mineral resources, which, in turn, assumes an overall dilution of 47% and a 94% mine recovery factor. The PEA also estimated the life of mine (“LOM”) revenues, basing its calculations on the long-term industry consensus forecast for metal prices. It also estimated the LOM operating costs, mining costs, LOM capital costs, pre-tax net present value (“NPV”), pre-tax internal rate of return (“IRR”), net cash flow, and after-tax NPV, after-tax cash flow, and after-tax IRR.

Expressing his satisfaction with the results of the PEA, which is focused solely on the current underground mineral resource, Mark Appleby, President and CEO of Tartisan, said, “There remains excellent potential to increase and upgrade the quality of the near-surface mineralization at Kenbridge thereby adding additional years of production or providing the basis for an increase in annual throughput.”

However, Appleby explained that the company would initially focus on underground mining, saying, “By adjusting the mining plan to be an underground operation, it allows Tartisan to utilize the existing shaft infrastructure, thereby accessing higher grades of mineralization early in the proposed mine life. The PEA provides compelling evidence to move toward feasibility and for the Kenbridge Nickel Project to move into production.”

Following the release of the PEA in 2022, Tartisan transitioned to the Advanced Exploration (“AEX”) and Project Development Phase, retaining Nordmin Engineering Ltd., a consulting engineering firm, to assist in developing a plan for this phase, according to a March 2023 news release (https://ibn.fm/zovIo). The company’s management believes that the AEX will expand the company’s understanding of the Kenbridge Deposit and enhance the current resource. Recently, Tartisan hired Northwest Solutions Inc. to provide road design, permitting, and project management support to the Kenbridge Nickel Project (https://ibn.fm/rK6C6).

For more information, visit the company’s website at www.TartisanNickel.com.

NOTE TO INVESTORS: The latest news and updates relating to TTSRF are available in the company’s newsroom at https://ibn.fm/TTSRF

BizCann invites traders, vendors, entrepreneurs, regulatory authorities, investors, and cannabis enthusiasts, to attend the BizCann Expo being held in Medellin, Colombia, May 18-19, 2024. The BizCann Expo is organized by ZJ Events, bringing the businesses and professionals of the cannabis industry and its ancillaries to a common forum for networking, trading, and learning sessions.

Having spread its reach over several cities in the US, BizCann Expo is being held in Medellin, Colombia, this year to offer phenomenal trading opportunities to local businesses. Due to its favorable location, connectivity, and rich history, Medellin offers the perfect venue for hosting this networking event.

In the year 2023, the event witnessed 50+ speakers, 200+ vendors, and 5,000+ attendees who connected over two days of networking and learning at the BizCann Expo. This year the participation is expected to outgrow last year’s numbers. Industry professionals with fresh and unique ideas can leverage this expo forum to gain visibility among peers, industry giants, and investors.

Entrepreneurs and creative minds with unique business ideas can share their innovations on this platform. Several eminent industry leaders will attend the expo to discuss the latest updates and strategies for successful canna trading. Plant-touching and non-plant touching cannabis businesses will also be represented at the Expo.

The speaker sessions will be conducted by stalwarts of the cannabis industry who have years of knowledge and experience of trading in this industry. They will discuss the latest updates, regulations, challenges, and prospects that lay ahead for businesses to grow and prosper. (Applications for speaker sessions are open.)

To learn more, please visit https://ibn.fm/HqJFj

The ZJ Events Vape South America 2024 will be held at the Plaza Mayor Convention Center, Medellin Colombia, May 18-19, 2024. Top manufacturers, buyers, suppliers, users, traders, enthusiasts, and stalwarts of the alternative products industry will be attending the always popular event.

The counterculture and vape trade show will showcase a myriad of alternative products that include herbal products, mood enhancers, vape products, functional beverages, dietary supplements, nootropics, and more.

Suppliers, traders, head shops, and several businesses from the alternative category, will be part of the Expo, to showcase their latest products and services. Attendees can leverage huge discounts, get amazing deals, and explore the most innovative products, all under the fun and exciting environment of the expo.

As traditional and mainstream marketing is difficult for alternative products, an exclusive channel must be available to market and showcase the alternative products. ZJ Events offers the counterculture industry a robust platform with their Alternative Products Expo, where the best of the industry influencers meet, connect, and collaborate.

The event offers:

• Registered buyers and brands, with media and marketing partnerships
• Mass exposure to new players, industries, and innovations in the counterculture realm
• Investors and traders, for discovering new products and trends
• Networking with industry veterans and distributors for network expansion and a better ROI
• Updates on the latest industry regulations

Vape South America started as Vape Conventions in 2017, evolved into USA CBDEXPO, and has been known as Alternative Products Expo in the United States since 2021. Dedicated booths are available for traders and innovators where they can showcase their innovative ideas and brands. Businesses can opt for different categories of sponsorships like platinum, gold, silver, etc., for extensive marketing by the event organizers.

To learn more, please visit https://ibn.fm/U1EwR